HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study

Ivonne Haffner(Leipzig University), Florian Lordick(Leipzig University), Birgitta Geier(Biomax Informatics (Germany)), Miriam Ahlborn(Klinikum Braunschweig), Christian Wittekind(University Hospital Leipzig), Katharina Kolbe(Leipzig University), Stefan Fuxius(Praxis für Hämatologie und Onkologie), Jan Hasenauer(University of Bonn), Katrin Schierle(University Hospital Leipzig), Gabriele Margareta Siegler(Nuremberg Hospital), Axel Walch(Unknown), Birgit Luber(Technical University of Munich), Beate Rau(Medizinische Hochschule Hannover), Jorge Riera Knorrenschild(Philipps University of Marburg), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Dieter Maier(Biomax Informatics (Germany)), Elba Raimúndez(Helmholtz Zentrum München), Albrecht Kretzschmar(Roche (Switzerland)), Thomas Decker
Journal of Clinical Oncology
March 25, 2021
10.1200/jco.20.02761
Cited by 124

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k